EU Medicines Regulation Achievements: EMA’...

By HEOR Staff Writer

March 16, 2026

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
FDA Biosimilar Approval Reforms: Accelerating Access and Reducing Drug Costs
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...